Australia's EchoIQ surges on launch of cardiology platform in U.S.
07/12/2022 03:24
** Shares of Australia's EchoIQ EIQ.AX rise as much as
10.5% to A$0.21, their highest since Aug. 2017
** The health and medical technology co launches EchoSolv to
the US cardiology sector
** EchoSolv is a cloud-based enhanced screening platform for
structural heart disease, commencing with aortic stenosis, which
is now available to registered customers in the US
** More than 2.4 mln shares change hands, compared with the
30-day average volume of 421,427 shares
** Stock has risen 31% this year, as of last close
(Reporting by Rishav Chatterjee in Bengaluru)
((Rishav.Chatterjee@thomsonreuters.com;))
Recent news on EchoIQ
See all newsAustralia's EchoIQ gains most in nearly 3 months after FDA update
Brief: EchoIQ Says FDA Raises No Concerns About Echosolv HF Technology Or Core Functionality
Australia's EchoIQ heads for worst week in seven years after US FDA setback
Australia's Echo IQ logs worst day in seven years after FDA setback
Brief: EchoIQ Requests Trading Halt